Cyclacel Pharmaceuticals (NASDAQ:CYCC) Rating Lowered to Sell at StockNews.com

Cyclacel Pharmaceuticals (NASDAQ:CYCC) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

Separately, Roth Mkm cut their price objective on Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, May 3rd.

Cyclacel Pharmaceuticals Price Performance

Cyclacel Pharmaceuticals stock opened at $1.62 on Thursday. Cyclacel Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $13.20. The business has a 50 day simple moving average of $2.00 and a 200-day simple moving average of $2.32. The stock has a market capitalization of $2.37 million, a PE ratio of -0.07 and a beta of 0.58.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($2.27) EPS for the quarter, topping the consensus estimate of ($4.93) by $2.66. Cyclacel Pharmaceuticals had a negative return on equity of 1,009.04% and a negative net margin of 4,401.34%. The business had revenue of $0.03 million during the quarter. During the same quarter last year, the company earned ($7.05) EPS. As a group, equities research analysts anticipate that Cyclacel Pharmaceuticals will post -4.93 EPS for the current year.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.